Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology

Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.

RTTNews | 289 days ago

Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY

Vertex Pharmaceuticals Inc. (VRTX) announced Friday that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

RTTNews | 397 days ago

CRISPR Therapeutics Says FDA Grants RMAT Designation To CTX130

Biopharmaceutical company CRISPR Therapeutics (CRSP) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the Company's wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS).

RTTNews | 840 days ago

Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that the company has entered into a definitive agreement under which Vertex will acquire privately-held biotechnology company ViaCyte for $320 million in cash.

RTTNews | 919 days ago

Vertex Pharma Says FDA Lifts Clinical Hold On Phase 1/2 Trial Of VX-880 To Treat Type 1 Diabetes

Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia.

RTTNews | 926 days ago

Quaker Oats Recalls Pearl Milling Original Pancake & Waffle Mix

Quaker Oats Co., affiliated to food and beverage giant PepsiCo, Inc., is recalling select Pearl Milling Co. Original Pancake & Waffle Mix distributed in 11 states, citing the possible presence of undeclared milk, a known allergen. According to the U.S. Food and Drug Administration, the recall involves a limited number of two pound boxes of Pearl Milling Original Pancake & Waffle Mix.

RTTNews | 6h 45min ago

European Economic News Preview: UK GDP Data Due

GDP monthly estimates and foreign trade from the UK and final inflation from Germany are due on Thursday, headlining a light day for the European economic news. At 2.00 am ET, the Office for National Statistics releases UK GDP, industrial production and foreign trade figures. Economists forecast the economy to grow 0.2 percent on month in November, in contrast to the 0.1 percent fall in October.

RTTNews | 6h 54min ago

Yen Rises Against Majors

The Japanese yen strengthened against other major currencies in the Asian session on Thursday.

RTTNews | 7h 0min ago

EURUSD	1.02945	GBPUSD	1.22076	AUDUSD	0.62162
USDJPY	156.028	USDCAD	1.43663	USDCHF	0.91169